Cyclacel Pharmaceuticals Stock Price

-0.30 (-3.97%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cyclacel Pharmaceuticals Inc CYCC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.30 -3.97% 7.25 18:14:58
Open Price Low Price High Price Close Price Prev Close
7.49 7.10 7.63 7.21 7.55
Bid Price Ask Price Spread News
7.21 7.25 0.04 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,352 209,156 $ 7.33 $ 1,532,256 781,303 3.12 - 19.25
Last Trade Time Type Quantity Stock Price Currency
18:14:58 formt 5,000 $ 7.25 USD

Cyclacel Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 35.26M 4.86M 4.82M $ - $ - -9.89 -1.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cyclacel Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CYCC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.929.467.107.70466,296-1.67-18.72%
1 Month6.359.776.198.26576,8010.9014.17%
3 Months3.319.773.126.75458,7283.94119.03%
6 Months4.489.773.125.82321,8342.7761.83%
1 Year16.0019.253.125.88421,687-8.75-54.69%
3 Years33.2038.603.1212.75317,685-25.95-78.16%
5 Years6.36218.003.1244.80344,8280.8913.99%

Cyclacel Pharmaceuticals Description

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

Your Recent History
Cyclacel P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.